Mielóma multiplex: vizsgálatok itt: Spanyolország
80 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisFelfüggesztveA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Where
- Salamanca, Santander
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00 - 1. fázisNot yet taking people in SpanyolországA Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
- Where
- Barcelona, Salamanca, Sevilla
- Életkor
- 18 év and over
- People
- 25 worldwide
- Run by
- TOLREMO therapeutics AG
See details and how to join2025-523536-39-00 - No phaseTaking peopleA Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
- Where
- Ávila, Granada, Madrid, Málaga, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Janssen-Cilag Ltd.
See details and how to joinNCT06285318 - 2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- Where
- Badalona, Córdoba, Gijón, Jerez de la Frontera, Madrid, Málaga, Salamanca, Vitoria
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00 - 3. fázisFut, nem toborozA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca, Santander, Sevilla, Terrassa, Toledo, Valencia
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - 1/2. fázisTaking peopleA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Barcelona, Gijón, Madrid, Móstoles, Murcia, Palma, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - 3. fázisNot yet taking people in SpanyolországStudy of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07764978 - 3. fázisTaking peopleA trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
- Where
- Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia
- Életkor
- 18 év and over
- People
- 153 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-523285-25-00 - 2. fázisTaking peopleA Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- Where
- Barcelona, Gijón, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Murcia, Terrassa
- Életkor
- 18 év and over
- People
- 116 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06140524 · EU 2023-505242-25-00 - 4. fázisTaking peopleElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Where
- Barcelona, Madrid, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00 - 1/2. fázisTaking peoplePhase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Murcia, Salamanca, Santander, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 62
- Run by
- Idp Discovery Pharma S.L.
See details and how to join2024-519194-19-00 - 3. fázisTaking peopleNDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
- Where
- Albacete, Alcalá de Henares, Badalona, Barcelona, Bilbao, Burgos, Cáceres, Gijón, Girona, Granada, Guadalajara, Jerez de la Frontera, León, Lleida, Logroño, Lugo, Madrid, Málaga, Móstoles, Murcia, Ourense, Oviedo, Palma de Mallorca, Pamplona, Pontevedra, Pozuelo de Alarcón, Salamanca, San Cristóbal de La Laguna, San Sebastián, San Sebastián de los Reyes, Santa Cruz de Tenerife, Santander, Santiago de Compostela, Segovia, Seville, Tarragona, Terrassa, Toledo, Valencia, Vitoria-Gasteiz, Zaragoza
- Életkor
- 18 év to 65 év
- People
- 480
- Run by
- PETHEMA Foundation
See details and how to joinNCT05558319 - 1/2. fázisTaking peopleStudy to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Where
- Badalona, Barcelona, Madrid, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- CellCentric Ltd.
See details and how to joinNCT04068597 - No phaseTaking peopleInfectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 350
- Run by
- Infanta Leonor University Hospital
See details and how to joinNCT07609576 - 3. fázisFut, nem toborozA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander, Valladolid
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - 2. fázisTaking peopleStudy for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- Where
- Barcelona, Las Palmas De Gran Canaria, Murcia, Salamanca
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT07107529 · EU 2024-520433-76-00 - 1. fázisTaking peopleStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Ichnos Sciences SA
See details and how to joinNCT05862012 · EU 2023-507071-21-01 - 1. fázisTaking peopleA Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 87 worldwide
- Run by
- Sanofi
See details and how to joinNCT06630806 - 3. fázisTaking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Badalona, Barcelona, Madrid, Santander, Valencia
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Albacete, Barcelona, Cáceres, Las Palmas, Madrid, Oviedo, Salamanca, Santander, Santiago de Compostela, Valencia
- Életkor
- 12 év and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555 - 1. fázisTaking peopleA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Where
- Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 187 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06153251 · EU 2023-506003-26-00 - No phaseTaking peopleReal-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
- Where
- Madrid, Palma
- Életkor
- 18 év and over
- People
- 75 worldwide
- Run by
- Takeda
See details and how to joinNCT05879757 - No phaseTaking peopleGammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
- Where
- Alcañiz, Almería, Ávila, Burgos, Girona, Granada, Huesca, Jaén, Lleida, Madrid, Málaga, Ourense, Palma de Mallorca, Ponferrada, Sabadell, Valdepeñas, Valencia, Valladolid, Vigo, Vitoria-Gasteiz
- Életkor
- 18 év to 99 év
- People
- 210
- Run by
- Fundación Española de Hematología y Hemoterapía
See details and how to joinNCT05992532 - 1/2. fázisFut, nem toborozA Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Badalona, Madrid, Santander
- Életkor
- 18 év and over
- People
- 260 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT05372354 · EU 2023-509384-25-00 - 2. fázisTaking peopleEfficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville, Valencia
- Életkor
- 18 év to 80 év
- People
- 30
- Run by
- PETHEMA Foundation
See details and how to joinNCT07045909